newsfilter
← Latest News
GlobeNewswire·

Tvardi Therapeutics Advances Next-Generation Oral STAT3 Inhibitor TTI-109 Toward IND in Inflammatory Bowel Disease Following FDA Pre-IND Feedback

  • Tvardi Therapeutics received constructive written responses from the FDA regarding its pre-IND meeting request for TTI-109, an oral STAT3 inhibitor.
  • The FDA agreed that the proposed nonclinical studies are appropriate to support Phase 2 clinical trials for TTI-109 in ulcerative colitis (UC) & Crohn's disease (CD).
  • Ulcerative colitis is the initial indication for TTI-109, with Crohn's disease evaluated as a potential additional indication due to shared STAT3 pathways.
  • The FDA provided guidance on dosing, study design, & patient selection to inform the Company's Investigational New Drug (IND) submission.
  • Tvardi plans to incorporate FDA feedback & submit an IND in 2027, subject to clearance & the availability of additional funding.
  • New data shows TTI-109 (as active form TTI-101) achieved levels in healthy volunteers sufficient to block STAT3 while minimizing inhibition of STAT1 & STAT5.
  • This selectivity profile differs from JAK inhibitors, which block multiple STAT pathways & carry boxed warnings for serious infections, mortality, & malignancy.
  • The Company believes preferential STAT3 inhibition may offer a differentiated safety profile, though safety in IBD patients remains unestablished.
  • TTI-109 is an orally administered prodrug that demonstrated pharmacodynamic evidence of STAT3 target engagement in a Phase 1 healthy volunteer study.
  • Tvardi is also conducting a Phase 1b/2 trial of TTI-101 in hepatocellular carcinoma (NCT05440708).
Company
Tvardi Therapeutics
Keywords
Nasdaq:TVRD, Tvardi Therapeutics